iTRAQ proteomics further confirmed MYBL2 as a top miR-29a-regulated protein.<h4>Conclusions</h4>MYBL2 is a potent diagnostic and prognostic biomarker in HCC that also predicts sorafenib sensitivity. This evidence concerns the gene MYBL2 and hepatocellular carcinoma.